LUCIDITY phase 3 topline data presented at CTAD for HMTM – the only oral anti-Tau therapy in late-stage development

– Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities – Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer’s Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco – For people with early […]

thaipr.net

1 ธ.ค. 65

TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions

For people with early Alzheimer’s (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals For people with mild to moderate Alzheimer’s, HMTM stabilised cognition and function and reduced rate of brain atrophy compared to historical matched individuals with AD HMTM […]

thaipr.net

6 ต.ค. 65

TauRx’s late-stage clinical trial reaches new milestone

– Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer’s – TauRx on track to announce top line results in May – Trial aims to confirm efficacy of first tau-based treatment for Alzheimer’s TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer’s Disease (AD) research, has announced that the last patient has completed treatment […]

thaipr.net

18 เม.ย. 65